Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dana L. Vanlandingham has a total of 61 co-authors. Here are the top co-authors by number of shared publications:

  • Stephen Higgs

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    13 shared publications
  • Yan-Jang S. Huang

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    9 shared publications
  • Susan M. Hettenbach

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    7 shared publications
  • So Lee Park

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    6 shared publications
  • Victoria B. Ayers

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    6 shared publications
  • Amy C. Lyons

    Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA

    4 shared publications

Latest Publications

  • Open Access

    From Risk to Response: a Dynamic Social-Ecological Systems Communication Framework for Reducing Vector-Borne Disease Incidence (Preprint)

    by Laura M. Moley, Sabah Bushaj, Kristin Michel, Douglas G. Goodin, Ashlie Ake, Dana L. Vanlandingham, McKenna F. Parnes

    UNSTRUCTURED Vector-borne diseases (VBDs) represent a rapidly growing public health challenge in the United States. Between 2001 and 2023, over one million VBD cases were reported, driven primarily by mosquito and tick-borne pathogens. Environmental change, including rising temperatures, shifting precipitation patterns, land use change, and suburban expansion into previously inhospitable habitats, has enabled vector populations to establish and thrive across new geographic ranges, accelerating both the incidence and geographic spread of VBDs. Despite this trajectory, VBD control in the U.S. remains highly fragmented and decentralized, organized primarily at the local or regional level with substantial heterogeneity in funding, technical capacity, and surveillance infrastructure. Current approaches to VBD control are predominantly reactive and triggered by outbreaks rather than driven by proactive, data-informed prevention. Critically, existing epidemiological models and control frameworks have not fully incorporated human behavioral variables (e.g., perception, outdoor activity patterns, mitigation behavior) into their assessments of transmission risk. This represents a fundamental gap, given that human behavior is both a driver of exposure and a modifiable target for intervention. Progress has been made in several adjacent areas. Environmental and climatic drivers of VBD transmission are increasingly well-characterized. Mathematical models have advanced considerably in their ability to forecast vector abundance, habitat suitability, disease risk under changing conditions while integrating data on human behavior. Public health communication theory has produced evidence-based principles for designing effective behavior change messaging. And tools from mathematical optimization and adaptive decision-making have demonstrated real-world utility in guiding surveillance and intervention allocation under resource constraints. However, these advances have largely developed in parallel rather than in integration. The 2024 Center for Disease Control and U.S. Department of Human Health Services Vector-Borne Disease National Strategy explicitly call for better understanding of individual exposure factors, improved prevention and control approaches, and more effective dissemination of detection and response tools, situated within a One Health framework to enhance coordination and communication across human, animal, and environmental contexts. This call makes the current moment particularly timely for an integrated framework that bridges biological, environmental, and social science approaches to VBD risk. This viewpoint responds to that need by proposing a dynamic social-ecological systems risk communication framework that integrates environmental surveillance data, vector and pathogen monitoring, mathematical optimization tools, and human behavioral and risk perception data into a cohesive, adaptive feedback system. The framework is designed to be generalizable across regions and VBD types, and to support evidence-based health policy and targeted public communication that is responsive to dynamic and spatially variable risk conditions. It is intended for an audience spanning epidemiology, public health, human behavior, geography, applied mathematics, and health policy.

  • A Review of Japanese Encephalitis Vaccines with Respect to Potential Veterinary Use

    by Audrey Matheny, Susan M. Hettenbach, Ashlie M. Ake, Stephen Higgs, Dana L. Vanlandingham

    Background: Japanese encephalitis virus (JEV) is a reemerging vector-borne orthoflavivirus of significant public and animal health concern. Infection with JEV can cause inapparent, mild, or fatal encephalitis in humans and animals. The virus, which circulates primarily in Southeast Asia, has caused outbreaks in humans and livestock in nonendemic regions, leading to human disease and significant economic loss. The 2022 Australian outbreak of JEV led to renewed interest in JEV countermeasures available in the United States for veterinary use as the Australia outbreak primarily affected commercial swine farms. There are currently no antivirals or veterinary vaccines available to protect animals from JEV infection, and only one vaccine is approved for human use in the United States. In the event of a JEV introduction to the United States, vaccination of susceptible reservoirs, like domestic swine, may help prevent economic loss and JEV from establishing endemicity in the United States. Methods: This review assesses recent advances in JEV vaccine development with an interest in veterinary applications. This systematic review was conducted by searching databases (PubMed, Web of Science, Scopus, and EBSCOhost). Results: Eighty-seven research articles focused on the evaluation of novel JEV vaccine candidates were included in this review. Conclusion: Although there are a variety of different methodologies being employed in the development of JEV vaccine candidates, including recombinant live virus vaccines utilizing insect-only flaviviruses as vectors for JEV antigens and virus-like particle vaccines using various JEV genes to elicit protection among different JEV genotypes. While there are many promising candidates being developed, most are likely several years away from commercial production and would not be available if JEV were introduced to the United States within the next several years. Therefore, other disease control strategies should be investigated.

  • Open Access

    Understanding the Burden of Agriculturally Significant Vector-Borne and Parasitic Diseases in Kansas

    by Kristin Michel, Nicole M. Ioerger, Ashlie M. Ake, Susan M. Hettenbach, Cassandra Olds, Dustin L. Pendell, James Stack, Stephen Higgs, Dana L. Vanlandingham

    Background: The state of Kansas (KS) has been called the “agricultural heartland” of the United States. Vector-borne and parasitic diseases (VBPD) have a major impact on the production of livestock, such as cattle, swine, goats and sheep, as well as crops, such as wheat, corn, and sorghum. The purpose of this review is to educate agricultural professionals in the state of KS about VBPD of current or potential concern and to inform the public about the challenges faced by the agricultural community. Methods: This review describes and discusses the endemic VBPD that currently impact agricultural production in KS and foreign VBPD of concern. In addition, we outline the major arthropod vectors of VBPD in KS, including ticks, mites, and various insects. In the context of this review, parasites are strictly limited to arthropod ectoparasites that negatively impact livestock production. Modern agricultural data for the state of KS were mostly sourced from the USDA National Agricultural Statistics Service, and current KS VBPD data were mostly sourced from the KS State Veterinary Diagnostic Laboratory. Conclusion: These VBPD have a large economic impact on the state and country, and we have concluded there is a need for updated estimates regarding the economic burden of VBPD in KS and throughout the United States to make better animal and crop health investment decisions.


  • Open Access

    Infection of Feral Phenotype Swine with Japanese Encephalitis Virus

    by So Lee Park, Yan-Jang S. Huang, Amy C. Lyons, Victoria B. Ayers, Susan M. Hettenbach, D. Scott McVey, Leela E. Noronha, Kenneth R. Burton, Stephen Higgs, Dana L. Vanlandingham

    Background: Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus and the leading cause of pediatric encephalitis in the Asian Pacific region. The transmission cycle primarily involves Culex spp. mosquitoes and Ardeid birds, with domestic pigs ( Sus scrofa domestica ) being the source of infectious viruses for the spillover of JEV from the natural endemic transmission cycle into the human population. Although many studies have concluded that domestic pigs play an important role in the transmission cycle of JEV, and infection of humans, the role of feral pigs in the transmission of JEV remains unclear. Since domestic and feral pigs are the same species, and because feral pig populations in the United States are increasing and expanding geographically, the current study aimed to test the hypothesis that if JEV were introduced into the United States, feral pigs might play a role in the transmission cycle. Materials and Methods: Sinclair miniature pigs, that exhibit the feral phenotype, were intradermally inoculated with JEV genotype Ib. These pigs were derived from crossing miniature domestic pig with four strains of feral pigs and were used since obtaining feral swine was not possible. Results: The Sinclair miniature pigs became viremic and displayed pathological outcomes similar to those observed in domestic swine. Conclusion: Based on these findings, we conclude that in the event of JEV being introduced into the United States, feral pig populations could contribute to establishment and maintenance of a transmission cycle of JEV and could lead to the virus becoming endemic in the United States.


  • Open Access

    Comparison of Immunogenicity Between a Candidate Live Attenuated Vaccine and an Inactivated Vaccine for Cache Valley Virus

    by Victoria B. Ayers, Yan-Jang S. Huang, Alain Kohl, James I. Dunlop, Susan M. Hettenbach, So Lee Park, Stephen Higgs, Dana L. Vanlandingham

    Cache Valley virus (CVV) is a mosquito-borne bunyavirus that is enzootic throughout the new world. Although CVV is known as an important agricultural pathogen, primarily associated with embryonic lethality and abortions in ruminants, it has recently been recognized for its expansion as a zoonotic pathogen. With the increased emergence of bunyaviruses with human and veterinary importance, there have been significant efforts dedicated to the development of bunyavirus vaccines. In this study, the immunogenicity of a candidate live-attenuated vaccine (LAV) for CVV, which contains the deletion of the nonstructural small (NSs) and nonstructural medium (NSm) genes (2delCVV), was evaluated and compared with an autogenous candidate vaccine created through the inactivation of CVV using binary ethylenimine (BEI) with an aluminum hydroxide adjuvant (BEI-CVV) in sheep. Both 2delCVV and BEI-CVV produced a neutralizing antibody response that exceeds the correlate of protection, that is, plaque reduction neutralization test titer >10. However, on day 63 postinitial immunization, 2delCVV was more immunogenic than BEI-CVV. These results warrant further development of 2delCVV as a candidate LAV and demonstrate that the double deletion of the NSs and NSm genes can be applied to the development of vaccines and as a common attenuation strategy for orthobunyaviruses.


  • Open Access

    Immunogenicity of a Candidate Live Attenuated Vaccine for Rift Valley Fever Virus with a Two-Segmented Genome

    by Victoria B. Ayers, Yan-Jang S. Huang, James I. Dunlop, Alain Kohl, Benjamin Brennan, Stephen Higgs, Dana L. Vanlandingham

    Rift Valley fever virus (RVFV) is an emerging arbovirus that affects both ruminants and humans. RVFV causes severe and recurrent outbreaks in Africa and the Arabian Peninsula with a significant risk for emergence into new locations. Although there are a variety of RVFV veterinary vaccines for use in endemic areas, there is currently no licensed vaccine for human use; therefore, there is a need to develop and assess new vaccines. Herein, we report a live-attenuated recombinant vaccine candidate for RVFV, based on the previously described genomic reconfiguration of the conditionally licensed MP12 vaccine. There are two general strategies used to develop live-attenuated RVFV vaccines, one being serial passage of wild-type RVFV strains to select attenuated mutants such as Smithburn, Clone 13, and MP12 vaccine strains. The second strategy has utilized reverse genetics to attenuate RVFV strains by introducing deletions or insertions within the viral genome. The novel candidate vaccine characterized in this report contains a two-segmented genome that lacks the medium viral segment (M) and two virulence genes (nonstructural small and nonstructural medium). The vaccine candidate, named r2segMP12, was evaluated for the production of neutralizing antibodies to RVFV in outbred CD-1 mice. The immune response induced by the r2segMP12 vaccine candidate was directly compared to the immune response induced by the rMP12 parental strain vaccine. Our study demonstrated that a single immunization with the r2segMP12 vaccine candidate at 10 5 plaque-forming units elicited a higher neutralizing antibody response than the rMP12 vaccine at the same vaccination titer without the need for a booster.


  • Open Access

    Replication Kinetics of a Candidate Live-Attenuated Vaccine for Cache Valley Virus in Aedes albopictus

    by Victoria B. Ayers, Yan-Jang S. Huang, James I. Dunlop, Alain Kohl, Benjamin Brennan, Stephen Higgs, Dana L. Vanlandingham

    Background: The emergence or re-emergence of several orthobunyaviruses (order: Bunyavirales ; family: Peribunyaviridae ), including Cache Valley virus (CVV) and Oropouche virus, warrants the development and evaluation of candidate live-attenuated vaccines (LAVs). Ideally, these vaccines would elicit long-lasting immunity with one single immunization. Materials and Methods: Since the deletion of two virulence factors, NSs and NSm, has been shown to attenuate the virulence phenotype of orthobunyaviruses, phleboviruses, and nairoviruses, genetic manipulation of the viral genome is considered an effective strategy for the rational design of candidate LAVs for bunyaviruses across multiple families. In addition, the deletion of Rift Valley fever virus NSs and NSm genes has been shown to reduce transmission by mosquitoes. Results: In this study, the ability of a CVV mutant lacking the NSs and NSm genes (2delCVV) to replicate in intrathoracically injected Aedes albopictus was compared with the parental wild-type CVV (wtCVV) 6V633 strain. In contrast to the robust replication of wtCVV in injected mosquitoes, the multiplication kinetics of the 2delCVV mutant was reduced by more than a 100-fold. Conclusion: These results suggest that the deletion of NSm and NSs genes is a feasible approach to rationally design candidate orthobunyavirus LAVs that are highly attenuated in mosquitoes and, therefore, pose little risk of reversion to virulence and transmission.


  • Open Access

    Re-Examining the Importance of Pigs in the Transmission of Japanese Encephalitis Virus

    by So Lee Park, Yan-Jang S. Huang, Dana L. Vanlandingham

    Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is the leading cause of pediatric encephalitis in Southeast Asia. The enzootic transmission of JEV involves two types of amplifying hosts, swine and avian species. The involvement of pigs in the transmission cycle makes JEV a unique pathogen because human Japanese encephalitis cases are frequently linked to the epizootic spillover from pigs, which can not only develop viremia to sustain transmission but also signs of neurotropic and reproductive disease. The existing knowledge of the epidemiology of JEV largely suggests that viremic pigs are a source of infectious viruses for competent mosquito species, especially Culex tritaeniorhynchus in the endemic regions. However, several recently published studies that applied molecular detection techniques to the characterization of JEV pathogenesis in pigs described the shedding of JEV through multiple routes and persistent infection, both of which have not been reported in the past. These findings warrant a re-examination of the role that pigs are playing in the transmission and maintenance of JEV. In this review, we summarize discoveries on the shedding of JEV during the course of infection and analyze the available published evidence to discuss the possible role of the vector-free JEV transmission route among pigs in viral maintenance.


  • Open Access

    SARS-CoV-2 and Arthropods: A Review

    by Stephen Higgs, Yan-Jang S. Huang, Susan M. Hettenbach, Dana L. Vanlandingham

    The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that led to the unprecedented COVID-19 pandemic exemplifies how a lack of understanding and preparedness for emerging viruses can result in consequences on a global scale. Statements that SARS-CoV-2 could not be transmitted by arthropod vectors were made without experimental support. Here we review laboratory-based research, field studies, and environmental studies to evaluate the potential for the virus to be transmitted either biologically or mechanically by arthropods. Based on these data, we conclude that transmission by arthropods is highly unlikely to play a significant epidemiological role in the transmission of SARS-CoV-2.


  • Open Access

    Mosquito Saliva Modulates Japanese Encephalitis Virus Infection in Domestic Pigs

    by So Lee Park, Yan-Jang S. Huang, Amy C. Lyons, Victoria B. Ayers, Susan M. Hettenbach, D. Scott McVey, Leela E. Noronha, Kenneth R. Burton, Wei-Wen Hsu, Stephen Higgs, et al.

    Japanese encephalitis virus (JEV) is a mosquito-borne flavivirus that is the leading cause of pediatric viral encephalitis in Asia. Japanese encephalitis virus is transmitted byCulexspecies mosquitoes that also vector several zoonotic flaviviruses. Despite the knowledge that mosquito saliva contains molecules that may alter flavivirus pathogenesis, whether or not the deposition of viruses by infected mosquitoes has an impact on the kinetics and severity of JEV infection has not been thoroughly examined, especially in mammalian species involved in the enzootic transmission. Most JEV pathogenesis models were established using needle inoculation. Mouse models for West Nile (WNV) and dengue (DENV) viruses have shown that mosquito saliva can potentiate flavivirus infections and exacerbate disease symptoms. In this study, we determined the impact of mosquito salivary components on the pathogenesis of JEV in pigs, a species directly involved in its transmission cycle as an amplifying host. Interestingly, co-injection of JEV and salivary gland extract (SGE) collected fromCulex quinquefasciatusproduced milder febrile illness and shortened duration of nasal shedding but had no demonstrable impact on viremia and neuroinvasion. Our findings highlight that mosquito salivary components can differentially modulate the outcomes of flavivirus infections in amplifying hosts and in mouse models.